Table 1.
Baseline clinical characteristics of male vs. female patients
| Characteristic | Male (n = 2,437) | Female (n = 1,308) | p-value |
|---|---|---|---|
| Age | 60.3 ± 11.6 | 64.7 ± 10.4 | < 0.0001* |
| BMI | 26.1 ± 6.5 | 24.3 ± 6.1 | < 0.0001† |
| Diabetes Mellitus | 1,041 (42.7) | 627 (47.9) | 0.011‡ |
| SAH | 1,652 (67,8) | 968 (72.9) | 0.001‡ |
| Smoking | 819 (33.6) | 332 (25.4) | < 0.0001‡ |
| FH positive for CAD | 361 (14.8) | 171 (12.9) | 0.113‡ |
| Dyslipidemia | 1,136 (46.6) | 666 (50.9) | 0.011‡ |
| Heart failure | 214 (8.8) | 133 (10) | 0.778‡ |
| Previous iCVA | 124 (5.1) | 67 (5.1) | 0.925‡ |
| Previous AMI | 819 (33.6) | 378 (28.9) | 0.004‡ |
| Previous CABG | 356 (14.6) | 140 (10.7) | 0.001‡ |
| Previous CA | 522 (21.4) | 234 (17.9) | 0.011‡ |
| Hemoglobin, mg/dL | 14.6 ± 1.9 | 13.2 ± 1.7 | < 0.001* |
| Peak troponin, ng/dL | 11.8 ± 5.9 | 8.0 ± 7.2 | < 0.001* |
| Creatinine, mg/dL | 1.3 ± 0.5 | 1.5 ± 0.4 | < 0.0001* |
| SBP, mmHg | 134.2 ± 29.4 | 133.0 ± 27.2 | 0.104† |
| LVEF,% | 52.3 ± 19.9 | 51.8 ± 18.7 | 0.09† |
| Killip ≥ 2 | 212 (8.7) | 99 (7.6) | 0.259‡ |
| ASA | 2,383 (97.8) | 1,267 (96.9) | 0.081‡ |
| Beta-blocker | 2,149 (88.2) | 1,105 (84.5) | 0.002‡ |
| GPI IIb/IIIa | 202 (8.3) | 114 (8.7) | 0.292‡ |
| Enoxaparin | 1,859 (76.3) | 981 (75) | 0.405‡ |
| Fondaparinux | 258 (10.6) | 128 (9.8) | 0.46‡ |
| Clopidogrel | 1,772 (72.7) | 920 (70.3) | 0.132‡ |
| Statins | 1,228 (50.4) | 647 (49.5) | 0.768‡ |
| ACE inhibitor | 1.694 (69.5) | 870 (66.5) | 0.065‡ |
Results are expressed as mean ± standard deviation, median ± standard deviation or n (%).
*
Unpaired t test;
†
Mann-Whitney U test;
‡
chi-square test. BMI: body mass index; SAH: systemic arterial hypertension; FH: family history; CAD: coronary artery disease; iCVA: ischemic cerebrovascular accident; AMI: acute myocardial infarction; CABG: coronary artery bypass grafting; CA: coronary angioplasty; SBP: systolic blood pressure; LVEF: left ventricular ejection fraction; ASA: acetylsalicylic acid; GPI: glycoprotein inhibitor; ACE inhibitor: angiotensin-converting enzyme inhibitor.